Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis.

Luca Moscetti,Claudia Omarini,Isabella Sperduti,Fabio Canino,Monica Barbolini,Cecilia Nasso,Angela Toss,Massimo Dominici,Federico Piacentini

Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis.

2021

Luca Moscetti
Claudia Omarini
Isabella Sperduti
Fabio Canino
Monica Barbolini
Cecilia Nasso
Angela Toss
Massimo Dominici
Federico Piacentini

e12516Background: The AET of HR+ EBC has been changing in the recent years. Aromatase inhibitors (AI) as upfront, or in a planned switch strategy after Tamoxifen (T), have been added to the choice ...

Keywords:

Internal medicine
Adverse effect
endocrine therapy
Medicine
Tamoxifen
Aromatase
Oncology
Adjuvant
Incidence (epidemiology)
Hormone receptor
early breast cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations